Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 11/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.56 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.56 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.56 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.56 |
| ▸ | ADH1B | P00325 | 1/20 | 0.55 |
| ▸ | ADH1C | P00326 | 1/20 | 0.55 |
| ▸ | ADH1A | P07327 | 1/20 | 0.55 |
| ▸ | ADH7 | P40394 | 1/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17715340 | 1.00 | SIGMAR1 (0.70) | SIGMAR1L3MBTL1S1PR2S1PR4S1PR1 | |
| SCHEMBL4311007 | 1.00 | SIGMAR1 (0.70) | SIGMAR1L3MBTL1S1PR2S1PR4S1PR1 | |
| SCHEMBL17715339 | 1.00 | SIGMAR1 (0.70) | SIGMAR1L3MBTL1S1PR2S1PR4S1PR1 | |
| SCHEMBL11077277 | 1.00 | SIGMAR1 (0.70) | SIGMAR1L3MBTL1S1PR2S1PR4S1PR1 | |
| SCHEMBL17715341 | 1.00 | SIGMAR1 (0.70) | SIGMAR1L3MBTL1S1PR2S1PR4S1PR1 | |
| SCHEMBL1270023 | 0.98 | SIGMAR1 (0.67) | SIGMAR1L3MBTL1S1PR2S1PR4S1PR1 | |
| SCHEMBL1356645 | 0.94 | SIGMAR1 (0.65) | SIGMAR1L3MBTL1ADH1BADH1CADH1A | |
| SCHEMBL56059 | 0.85 | ADH1B (0.61) | SIGMAR1L3MBTL1ADH1BADH1CADH1A | |
| SCHEMBL9819797 | 0.83 | SIGMAR1 (1.00) | SIGMAR1 | |
| SCHEMBL9819830 | 0.83 | SIGMAR1 (1.00) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2478981-B1 | SILVER-(CONJUGATED COMPOUND) COMPLEX | SUMITOMO CHEMICAL CO (JP) | 2020-12-23 | — | — | EP | disclosed |
| US-9704612-B2 | Composition of silver-conjugated compound composite | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-07-11 | — | — | US | disclosed |
| US-9412487-B2 | Silver-(conjugated compound) composite | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-08-09 | — | — | US | disclosed |
| US-20150376124-A1 | ANTI-CANCER COMPOSITIONS AND METHODS | PENN STATE RES FOUND (US) | 2015-12-31 | — | — | US | disclosed |
| US-9126911-B2 | Anti-cancer compositions and methods | THE PENN STATE RESEARCH FOUNDATION (US) | 2015-09-08 | — | — | US | disclosed |
| US-9126910-B2 | Anti-cancer compositions and methods | THE PENN STATE RESEARCH FOUNDATION (US) | 2015-09-08 | — | — | US | disclosed |
| US-9096505-B2 | Anti-cancer compositions and methods | THE PENN STATE RESEARCH FOUNDATION (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140001422-A1 | COMPOSITION OF SILVER-CONJUGATED COMPOUND COMPOSITE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-01-02 | — | — | US | disclosed |
| US-20130253052-A1 | ANTI-CANCER COMPOSITIONS AND METHODS | THE PENN STATE RESEARCH FOUNDATION (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130184340-A1 | ANTI-CANCER COMPOSITIONS AND METHODS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-07-18 | — | — | US | disclosed |
| WO-1998004542-A1 | CHROMAN DERIVATIVES | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1998-02-05 | — | — | WO | disclosed |
| US-5688823-A | ANTILIPEMIC AGENTS, ANTIGLYCEMIC AGENTS, OBESITY, GLUCOSE TOLERANCE INSUFFICIENCY, INSULIN RESISTANCE AND DIABETIC COMPLICATIONS | SANKYO COMPANY, LIMITED (JP) | 1997-11-18 | — | — | US | disclosed |
| EP-0765314-A1 | BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-04-02 | — | — | EP | disclosed |
| US-5578620-A | TREATMENT OF DIABETES AND HYPERLIPEMIA | SANKYO COMPANY, LIMITED (JP) | 1996-11-26 | — | — | US | disclosed |
| EP-0696586-A1 | SERINE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1996-02-14 | — | — | EP | disclosed |
| WO-1995034540-A1 | BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-12-21 | — | — | WO | disclosed |
| EP-0678511-A2 | Thiazolidine and oxazolidine derivatives, their preparation and their medical use | SANKYO COMPANY LIMITED (JP) | 1995-10-25 | — | — | EP | disclosed |
| US-4971957-A | ANTILIPEMIC AGENTS, ANTICHOLESTEROL AGENTS, BENZENECARBOXAMIDOPHOSPHONATES OR BENZENETHIOCARBOXAMIDOPHOSPHONATES | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1990-11-20 | — | — | US | disclosed |
| US-4906662-A | Phenol derivatives, their preparation and the use thereof | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1990-03-06 | — | — | US | disclosed |
| EP-0263229-A1 | Phenol derivatives, their preparation and the use thereof | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1988-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376124-A1 | ANTI-CANCER COMPOSITIONS AND METHODS | MKI67, BAX, BCL2 | SIGMAR1 2821/4885L3MBTL1 1539/4885S1PR2 3711/4885 |
| US-20130253052-A1 | ANTI-CANCER COMPOSITIONS AND METHODS | MKI67, BAX, BCL2 | SIGMAR1 2821/4885L3MBTL1 1539/4885S1PR2 3711/4885 |
| US-20130184340-A1 | ANTI-CANCER COMPOSITIONS AND METHODS | MKI67, BAX, BCL2 | SIGMAR1 2821/4885L3MBTL1 1539/4885S1PR2 3711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.